PAVmed Inc. to Hold Business Update Conference Call on May 17th

Wednesday, May 10, 2017 8:30 am EDT

Dateline:

NEW YORK

Public Company Information:

NASDAQ:
PAVM
NASDAQ:
PAVMW

NEW YORK--(BUSINESS WIRE)--PAVmed Inc. (NASDAQ:PAVM; PAVMW), a highly differentiated, multi-product medical device company, today announced that the Company will host a conference call on May 17, 2017 at 4:30 p.m. Eastern time. During this call Lishan Aklog, M.D., the Company’s Chairman and Chief Executive Officer, and Brian de Guzman, M.D., the Company’s Chief Medical Officer, will provide a business update including an overview of the Company’s near-term milestones and growth strategy, as well as a focused discussion of its percutaneous CarpX™ device designed to treat Carpal Tunnel Syndrome without the need for open surgery. In addition, Dennis McGrath, the Company’s Chief Financial Officer will discuss first quarter 2017 financial results, which will be announced on May 15th after the close of the market.

To access the conference call, U.S.-based listeners should dial (888) 803-5993 and international listeners should dial (706) 634-5454. All listeners should provide the following passcode: 19406912. Individuals interested in listening to the live conference call via the Internet may do so by visiting the Company’s website at www.pavmed.com.

Following the conclusion of the conference call, a replay will be available through May 23, 2017 and can be accessed by dialing (855) 859-2056 from within the U.S. or (404) 537-3406 from outside the U.S. All listeners should provide passcode 19406912. The webcast will be available for 90 days.

About PAVmed Inc.

PAVmed Inc. (Nasdaq: PAVM, PAVMW) is a highly differentiated, multi-product medical device company employing a unique business model designed to advance products from concept to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding multi-product pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs, have attractive regulatory pathways and market opportunities and encompass a broad spectrum of clinical areas including carpal tunnel syndrome (CarpX™), medical infusions (NextFlo™ and NextCath™), interventional radiology (PortIO™ and NextCath), tissue ablation and cardiovascular intervention (Caldus™) and pediatric ear infections (DisappEAR™). For further information, please visit www.pavmed.com.

Safe Harbor Statement

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of the Company’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, the uncertainties inherent in research and development, including the cost and time required advance our products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from our pre‐clinical studies; whether and when our products are cleared by regulatory authorities; market acceptance of our products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market any of its products. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA, “Risk Factors,” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Reports on Form 10-Q filed by us after our most recent Annual Report. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Contact:

Investors
LHA
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Media
RooneyPartners
Kate Barrette, 212-223-0561
kbarrette@rooneyco.com

SEC Filings

Click Here to view PAVmed's SEC filings

INVESTOR PRESENTATION

Click Here to view PAVmed’s current Investor Presentation

PROXY MATERIALS

Click Here to view the Proxy Statement for PAVmed Inc 2017 Annual Meeting

Click Here view the Annual Report for PAVmed Inc 2017 Annual Meeting